Morphine (Chlorhydrate) Renaudin (Morphine Hydrochloride)

Morphine binds as a full agonist to µ‑opioid receptors in the brain, spinal cord and peripheral nervous system. This binding inhibits the release of excitatory neurotransmitters, reduces neuronal firing, and alters the perception of pain, producing both analgesic and sedative effects.

The dose of morphine is individualized by the prescribing clinician based on factors such as the intensity of pain, patient age, weight, renal and hepatic function, prior opioid exposure, and the route of administration. No universal dosing regimen is provided.

Safety data for morphine in pregnancy and lactation are limited. Because opioids can cross the placenta and enter breast milk, morphine is generally used only when the potential benefit justifies the potential risk to the fetus or infant. Consultation with a specialist is recommended.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and the necessary import documentation.

Morphine is considered a benchmark opioid because of its strong µ‑receptor affinity and well‑characterized efficacy. Compared with weaker opioids such as codeine, morphine provides more potent analgesia but also carries a higher risk of respiratory depression and dependence. It is often used when less potent agents are insufficient.

Morphine (Chlorhydrate) Renaudin should be stored below 25 °C in its original packaging. Protect the vials from moisture, light and extreme temperature fluctuations. Do not freeze the product, and keep it out of reach of unauthorized personnel.

The product is supplied as a sterile injectable solution and may be given intravenously or subcutaneously by a qualified healthcare professional. Administration technique, infusion rate and monitoring are determined by the prescriber according to clinical guidelines and patient response.

The most critical risks include respiratory depression, profound hypotension, severe allergic reactions (anaphylaxis), and the potential for physical dependence, tolerance and addiction. Continuous monitoring, especially during dose initiation and titration, is essential to detect these events early.

Morphine is contraindicated in patients with known hypersensitivity to morphine or other opioids, those with uncontrolled severe respiratory depression, acute asthma attacks, or paralytic ileus. Caution is also advised in individuals with significant hepatic or renal impairment, and in patients taking certain interacting medications.